Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 5;14(4):e082957.
doi: 10.1136/bmjopen-2023-082957.

Protocol for evaluating the effects of the Reducing Cardiometabolic Diseases Risk dietary pattern in the Chinese population with dyslipidaemia: a single-centre, open-label, dietary intervention study

Qi Wu  1 , Liyang Zhang  1 , Cheng Cheng  1 , Xukun Chen  1 , Shanshan Bian  2 , Li Huang  1 , Tongtong Li  1 , Zhenshu Li  1   3 , Huan Liu  1   3   4 , Jing Yan  3   4   5 , Yue Du  3   4   5 , Yongjie Chen  3   4   6 , Meilin Zhang  1   3   4 , Lichun Cao  7 , Wen Li  1   3   4 , Fei Ma  8   4   6 , Guowei Huang  9   3   4   10
Affiliations

Protocol for evaluating the effects of the Reducing Cardiometabolic Diseases Risk dietary pattern in the Chinese population with dyslipidaemia: a single-centre, open-label, dietary intervention study

Qi Wu et al. BMJ Open. .

Abstract

Introduction: Cardiometabolic disease (CMD) is the leading cause of mortality in China. A healthy diet plays an essential role in the occurrence and development of CMD. Although the Chinese heart-healthy diet is the first diet with cardiovascular benefits, a healthy dietary pattern that fits Chinese food culture that can effectively reduce the risk of CMD has not been found.

Methods/design: The study is a single-centre, open-label, randomised controlled trial aimed at evaluating the effect of the Reducing Cardiometabolic Diseases Risk (RCMDR) dietary pattern in reducing the risk of CMDs in people with dyslipidaemia and providing a reference basis for constructing a dietary pattern suitable for the prevention of CMDs in the Chinese population. Participants are men and women aged 35-45 years with dyslipidaemia in Tianjin. The _target sample size is 100. After the run-in period, the participants will be randomised to the RCMDR dietary pattern intervention group or the general health education control group with a 1:1 ratio. The intervention phases will last 12 weeks, with a dietary intervention of 5 working days per week for participants in the intervention group. The primary outcome variable is the cardiometabolic risk score. The secondary outcome variables are blood lipid, blood pressure, blood glucose, body composition indices, insulin resistance and 10-year risk of cardiovascular diseases.

Ethics and dissemination: The study complies with the Measures for Ethical Review of Life Sciences and Medical Research Involving Human Beings and the Declaration of Helsinki. Signed informed consent will be obtained from all participants. The study has been approved by the Medical Ethics Committee of the Second Hospital of Tianjin Medical University (approval number: KY2023020). The results from the study will be disseminated through publications in a peer-reviewed journal.

Trial registration number: Chinese Clinical Trial Registry (ChiCTR2300072472).

Keywords: Cardiovascular Disease; DIABETES & ENDOCRINOLOGY; NUTRITION & DIETETICS; Randomized Controlled Trial.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
The flow chart of the study. CVD, cardiovascular disease; RCMDR, Reducing Cardiometabolic Diseases Risk.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Castro JP, El-Atat FA, McFarlane SI, et al. . Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003;5:393–401. 10.1007/s11906-003-0085-y - DOI - PubMed
    1. The WCOTROCHADIC . Report on cardiovascular health and diseases in China 2022: an updated summary. Biomed Environ Sci 2023;36:669–701. 10.3967/bes2023.106 - DOI - PubMed
    1. Ralston J, Nugent R. Toward a broader response to cardiometabolic disease. Nat Med 2019;25:1644–6. 10.1038/s41591-019-0642-9 - DOI - PubMed
    1. Li J-J, Zhao S-P, Zhao D, et al. . Chinese guideline for lipid management. Front Pharmacol 2023;14:1190934. 10.3389/fphar.2023.1190934 - DOI - PMC - PubMed
    1. Kaze AD, Santhanam P, Musani SK, et al. . Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look ahead study. J Am Heart Assoc 2021;10:e016947. 10.1161/JAHA.120.016947 - DOI - PMC - PubMed

Publication types

LinkOut - more resources

  NODES
COMMUNITY 2
innovation 2
twitter 2